Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Welcome Email

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
GLP-1RA, Other, Topics

Pfizer Initiates Ph3 Berobenatide OSA Study; Novo Ph3 Zenagamtide Study in Japan; Novo and Anthropic Partner for Drug and AI Development

Here is a brief preview of this blast: Three cardiometabolic-related news items have been observed: Pfizer initiated the Ph3 QM berobenatide VESPER-OSA 1 study (view CT.gov record); Novo initiated the zenagamtide AMAZE 10 study in Japanese patients with obesity (view CT.gov record); and Novo and Anthropic entered into a collaboration to accelerate Novo’s drug development and AI-driven software development (view press release). Below, FENIX provides highlights and insights for the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.